Xeris Pharmaceuticals
General Information | |
Business: |
We are a specialty pharmaceutical company leveraging our novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. We have developed a ready-to-use, room-temperature stable liquid glucagon formulation that, unlike any currently available products, can be administered without any preparation or reconstitution. Our lead product candidate, Glucagon Rescue Pen, delivers ready-to-use glucagon via a commercially-available auto-injector for the treatment of severe hypoglycemia, a potentially life-threatening condition, in people with diabetes.
|
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 55 |
Founded: | 2005 |
Contact Information | |
Address | 180 N. LaSalle Street, Suite 1810, Chicago, IL 60601, US |
Phone Number | 1-844-445-5704 |
Web Address | http://www.xerispharma.com |
View Prospectus: | Xeris Pharmaceuticals |
Financial Information | |
Market Cap | $296.0mil |
Revenues | $1.4 mil (last 12 months) |
Net Income | $-33.8 mil (last 12 months) |
IPO Profile | |
Symbol | XERS |
Exchange | NASDAQ |
Shares (millions): | 5.7 |
Price range | $15.00 - $15.00 |
Est. $ Volume | $85.5 mil |
Manager / Joint Managers | Jefferies/ Leerink Partners/ RBC Capital Markets |
CO-Managers | Mizuho Securities |
Expected To Trade: | 6/21/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |